Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.

Virchows Archiv : an international journal of pathology - 1 Apr 2023

Vollbrecht Claudia, Hoffmann Inga, Lehmann Annika, Merkelbach-Bruse Sabine, Fassunke Jana, Wagener-Ryczek Svenja, Ball Markus, Dimitrova Lora, Hartmann Arndt, Stöhr Robert, Erber Ramona, Weichert Wilko, Pfarr Nicole, Bohlmann Lisa, Jung Andreas, Dietmaier Wolfgang, Dietel Manfred, Horst David, Hummel Michael

Abstract excerpt

Precision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries-including Germany-assays employed for this purpose are highly diverse and not prescribed by authorities, making inter-laboratory comparison difficult. To ensure reproducible molecular diagnostic results across many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Europe

Share to Mutation

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 36367572
DOI: 10.1007/s00428-022-03445-x
PMCID: PMC10067656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.PMID 36367572Read ↗

Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue.Semantic proximity Read ↗

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.Semantic proximity Read ↗

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.Semantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

[What's new liquid biopsy-PIK3CA testing in breast cancer].Semantic proximity Read ↗

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.Semantic proximity Read ↗

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.Semantic proximity Read ↗

Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.Semantic proximity Read ↗

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Semantic proximity Read ↗

Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path).Semantic proximity Read ↗

What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.